Banca de QUALIFICAÇÃO: Rafaella Albuquerque e Silva

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : Rafaella Albuquerque e Silva
DATE: 20/12/2023
TIME: 09:00
LOCAL: Plataforma TEAMS
TITLE:

Factors associated with  human visceral leishmaniasis relapse in Brazil

KEY WORDS:

Visceral leishmaniasis; Relapse; Predictive models; Prognosis.

PAGES: 56
BIG AREA: Ciências da Saúde
AREA: Medicina
SUBÁREA: Clínica Médica
SPECIALTY: Doenças Infecciosas e Parasitárias
SUMMARY:

Ministry of Health defines relapse in visceral leishmaniasis (VL) as recurrence of symptoms within 12 months after clinical cure. It is considered a risk factor for death, but few studies have evaluated the factors inherent to its occurrence besides co-infection with HIV. In this sense, the aim of this study is to develop and validate a predictive model of relapse after treatment in VL patients in Brazil. For the characterization of cases and potential risk factors, such as factors related to immunodeficiency (co-infection with HIV) and immunosuppression (transplant recipients), secondary databases from both official information systems and medical records will be used. Demographic, clinical, access and socio-environmental variables will be used. Aggregated data will be obtained from IBGE, e-SUS-AB and e-Gestor databases. Between 2014 and 2020, 23,581 cases of VL were confirmed, with an annual average of 3,368 cases/year. Stratified by type of entry, new case or relapse, respectively, 66% and 70% were male, 74.2% and 67.3% were brown, and 57% and 49% had up to 8th grade education. The most frequent clinical manifestations are fever, hepatomegaly, weakness and pallor. The use of meglumine antimoniate was the most frequently used drug in new cases of VL, while liposomal amphotericin B was used in patients with relapse. The descriptive component will support the choice of the best variables for the construction of the prediction model, however the data are still being obtained. The definition of these variables will allow an improvement in the establishment of lines of care and assertive therapeutic protocols, with a view to reducing not only relapse, but also death. VL control programs in endemic areas can use risk prediction models to strategically target patients who are more susceptible to treatment failure and ensure their recovery.

COMMITTEE MEMBERS:
Presidente - 2279074 - GUSTAVO ADOLFO SIERRA ROMERO
Interna - 484663 - ELISABETH CARMEN DUARTE
Interno - 1961891 - WILDO NAVEGANTES DE ARAUJO
Externa à Instituição - GLAUCIA FERNANDES COTA - FIOCRUZ-MG
Externo à Instituição - VINICIUS SILVA BELO - UFSJ